1 |
Adam BL, Qu Y, Davis JW, et al (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 62, 3609-14.
|
2 |
DiMagno EP, Reber HA, Tempero MA (1999). Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 117, 1463-84.
DOI
ScienceOn
|
3 |
Ebert MP, Meuer J, Wiemer JC, et al (2004). Identification of gastric cancer patients by serum protein profiling. J Proteome Res, 3, 1261-6.
DOI
|
4 |
Guo R, Pan C, Shen J, et al (2011). New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Cancer Res Clin Oncol, 137, 513-9.
DOI
|
5 |
Hortin GL (2006). The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem, 52, 1223-37.
DOI
|
6 |
Liu C, Pan C, Shen J, et al (2011). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci, 8, 39-47.
DOI
|
7 |
Liu C, Wang H, Pan C, et al (2010). Serum protein fingerprint of patients with gastric cancer by SELDI technology. African J Biotechnol, 9, 2298-304.
|
8 |
Kim JE, Lee KT, Lee JK, et al (2004). Clinical usefulness of Carbohydrate antigen 199 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol, 19, 182-6.
DOI
|
9 |
Kim EJ, Simeone DM, (2011). Advances in pancreatic cancer. Curr Opin Gastroenterol, 27, 460-6.
DOI
|
10 |
Liang Y, Fang M, Li J, et al (2006). Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol, 81, 176-80.
DOI
|
11 |
Li D, Xie K, Wolff R, et al (2004). Pancreatic cancer. Lancet, 363, 1049-57.
DOI
ScienceOn
|
12 |
Liotta LA, Ferrari M, Petricoin E (2003). Clinical proteomics: written in blood. Nature, 425, 905.
DOI
|
13 |
Liu CB, Liang Y, Pan CQ, et al (2009). Proteome study of differential protein expression in HBV-related primary hepatic carcinoma. Chem J Chinese Universities, 30, 1763-6.
|
14 |
Liu C, Shen J, Pan C, et al (2010). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol, 134, 235-41
DOI
|
15 |
Schwegler EE, Cazares L, Steel LF, et al (2005). SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology, 41, 634-42.
DOI
|
16 |
Ward DG, Cheng Y, N'Kontchou G, et al (2006). Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer, 95, 1379-83.
DOI
|
17 |
Semmes OJ, Feng Z, Adam BL, et al (2005). Evaluation of serum protein profiling by surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem, 51, 102-12.
|
18 |
Singh S, Tang SJ, Sreenarasimhaiah J, et al (2011). The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci, 56, 2491-6.
DOI
|
19 |
Wagner M, Naik DN, Pothen A, et al (2004). Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics, 5, 26.
DOI
|
20 |
Ward DG, Suggett N, Cheng Y, et al (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer, 94, 1898-905.
DOI
|